Premium
RANDOMIZED, DOUBLE‐BLIND TRIAL OF EXIFONE VERSUS COGNITIVE PROBLEMS IN PARKINSON'S DISEASE
Author(s) -
ALLAIN H.,
DENMAT J.,
BENTUEFERRER D.,
MILON D.,
PIGNOL P.,
REYMANN J.M.,
PAPE D.,
SABOURAUD O.,
DRIESSCHE J.
Publication year - 1988
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1988.tb00615.x
Subject(s) - placebo , cognition , parkinson's disease , double blind , disease , medicine , recall , dose , clinical trial , psychology , psychiatry , pathology , cognitive psychology , alternative medicine
Summary— Exifone is a novel substance of the benzophenone group that possesses potent scavenging properties. Initial findings demonstrate beneficial effects on age‐related cognitive disorders. In this double‐blind clinical trial versus placebo, the efficacy of 2 dosages (600 and 1200 mg/d) was evaluated with regard to Parkinson's disease (PD)‐related cognitive disorders, for which there is increasing suspicion of a free‐radicals origin. Despite disparities between the treatment groups as assessed by validated scales and subtests, and a considerable placebo effect on main parameters, both dose levels of exifone produced statistically significant improvement of the cognitive items most commonly impaired by PD: immediate recall, naming of objects presented, spatiotemporal orientation, and calculation. These properties suggest a new slot for exifone in the range of therapeutics available.